Combat Drug-resistant TB on War Footing

Published: 03rd July 2014 06:00 AM  |   Last Updated: 03rd July 2014 12:51 AM   |  A+A-

Given that India has the highest burden for tuberculosis (TB) in the world, it is welcome news that scientists in India and the US have managed to modify a precursor to an existing anti-TB drug. This will now aid the development of new antibiotics that can be used against drug-resistant TB. The new analogue of this drug is a significant breakthrough in the treatment of the virulent forms of TB. One of the main reasons of the lacklustre performance of India’s current campaign against TB is that a bulk of the patients, usually from the lower economic sections, often stop medication at the first sign of recovery. Since the new drug brings down the course of treatment, more patients are likely to complete the course, thereby checking the spread of MDR and XDR TB.

If it works—and it has been successful in smaller trials—the new trial announced by the global TB Alliance will be carried out by partners around the world. It will cut the length of a course of pills for TB from six months to four and for MDR-TB from 18-24 months down to six. There will be no more need for daily injections for MDR-TB, and the Alliance says the patients will be taking maybe 360 pills or less instead of more than 14,000 over the course of their treatment, as now, and the drugs will be less toxic. TB kills 1.4 million people a year. The old drugs—half a century old—are no longer adequate.

In 1993, resurgent levels of TB due to the antibiotic resistance led the WHO to declare it a global health emergency. But not much has changed in the intervening years. There is, however, considerable promise in the new regimen and the secret will lie in a concerted drive to defeat the drug resistance in rifampicin and related antibiotics through a new compound with a combination of genetic modification and synthetic drug development. It is heartening that India is engaged with the US to devise the new compound but more vigorous efforts are needed.

Stay up to date on all the latest Editorials news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp